Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus
OBJECTIVES: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867648/ https://www.ncbi.nlm.nih.gov/pubmed/31747435 http://dx.doi.org/10.1371/journal.pone.0225516 |
_version_ | 1783472113377607680 |
---|---|
author | Jiang, N. Li, M. Zhang, M. Xu, J. Jiang, L. Gong, L. Wu, F. Gu, J. Zhao, J. Xiang, Y. Wang, Z. Zhao, Y. Zeng, X. |
author_facet | Jiang, N. Li, M. Zhang, M. Xu, J. Jiang, L. Gong, L. Wu, F. Gu, J. Zhao, J. Xiang, Y. Wang, Z. Zhao, Y. Zeng, X. |
author_sort | Jiang, N. |
collection | PubMed |
description | OBJECTIVES: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm(3) at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm(3). The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated. RESULTS: Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%). CONCLUSIONS: Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia. |
format | Online Article Text |
id | pubmed-6867648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-68676482019-12-07 Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus Jiang, N. Li, M. Zhang, M. Xu, J. Jiang, L. Gong, L. Wu, F. Gu, J. Zhao, J. Xiang, Y. Wang, Z. Zhao, Y. Zeng, X. PLoS One Research Article OBJECTIVES: To investigate the prevalence, clinical characteristics, and prognosis of thrombocytopenia (TP) in Chinese patients with systemic lupus erythematosus (SLE). METHODS: The study was conducted based on the Chinese SLE Treatment and Research group (CSTAR) registry. Thrombocytopenia was defined as the platelet count<100,000/mm(3) at enrollment. Severe thrombocytopenia was defined as the platelet count<50,000/mm(3). The prevalence of SLE-related TP, the associations of thrombocytopenia with demographic data, organ involvements, laboratory findings, disease activity, damage, and mortality were investigated. RESULTS: Of 2104 patients with SLE, 342 patients (16.3%) were diagnosed with thrombocytopenia. The prevalence of neuropsychiatric SLE, vasculitis, myositis, nephritis, mucocutaneous lesions, pleuritis, fever, leukocytopenia and hypocomplementemia were significantly higher in patients with thrombocytopenia (p<0.05). SLE disease activity index (SLEDAI) was significantly higher in patients with thrombocytopenia (p<0.05). Multivariate analysis showed that leukocytopenia (OR = 2.644), lupus nephritis (OR = 1.539), hypocomplementemia (OR = 1.497) and elevated SLEDAI (OR = 1.318) were independently associated with thrombocytopenia (p<0.05). Long disease duration (OR = 1.006) was an independent risk factor of severe thrombocytopenia, while anti-rRNP (OR = 0.208) was an independent protective factor of severe thrombocytopenia (p<0.05). Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia (RR = 1.006). The 6-year survival of patients with thrombocytopenia was significantly lower than patients without thrombocytopenia (88.2% vs. 95.5%). CONCLUSIONS: Thrombocytopenia was a common manifestation of SLE and was associated with leukocytopenia, nephritis and severe disease activity. Severe thrombocytopenia tended to occur in long-term and relatively inactive SLE. Patients with SLE-related thrombocytopenia has a decreased long-term survival rate. Long disease duration was an independent risk factor of mortality in patients with thrombocytopenia. Public Library of Science 2019-11-20 /pmc/articles/PMC6867648/ /pubmed/31747435 http://dx.doi.org/10.1371/journal.pone.0225516 Text en © 2019 Jiang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Jiang, N. Li, M. Zhang, M. Xu, J. Jiang, L. Gong, L. Wu, F. Gu, J. Zhao, J. Xiang, Y. Wang, Z. Zhao, Y. Zeng, X. Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus |
title | Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus |
title_full | Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus |
title_fullStr | Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus |
title_full_unstemmed | Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus |
title_short | Chinese SLE Treatment and Research group (CSTAR) registry: Clinical significance of thrombocytopenia in Chinese patients with systemic lupus erythematosus |
title_sort | chinese sle treatment and research group (cstar) registry: clinical significance of thrombocytopenia in chinese patients with systemic lupus erythematosus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867648/ https://www.ncbi.nlm.nih.gov/pubmed/31747435 http://dx.doi.org/10.1371/journal.pone.0225516 |
work_keys_str_mv | AT jiangn chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT lim chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT zhangm chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT xuj chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT jiangl chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT gongl chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT wuf chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT guj chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT zhaoj chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT xiangy chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT wangz chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT zhaoy chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT zengx chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus AT chinesesletreatmentandresearchgroupcstarregistryclinicalsignificanceofthrombocytopeniainchinesepatientswithsystemiclupuserythematosus |